ClinicalTrials.gg
CompletedNCT07331194Updated Feb 12, 2026

Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans

A Phase 1 interventional study of HMPL-523 Acetate Tablets (Test Formulation) and HMPL-523 Acetate Tablets (Reference Formulation) in Healthy, sponsored by Hutchmed. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Two formulations containing the same active pharmaceutical ingredient are considered bioequivalent if their relative bioavailability (rate and extent of drug absorption) falls within acceptable predetermined limits after administration at the same molar dose. Formulations with bioequivalence are considered to act comparably in vivo, i.e., similar in terms of safety and efficacy.

This study aims to evaluate the pharmacokinetic (PK) profile and bioequivalence of the original and modified formulations of HMPL-523 acetate tablets in healthy participants to bridge the safety and efficacy of the modified formulation of HMPL 523 acetate tablets in humans.

Read the detailed description

This study adopts a single-center, randomized, open-label, single-dose, four-cycle, fully replicate clinical trial design to evaluate the PK profile and bioequivalence of two different formulations of HMPL-523 acetate tablets in healthy participants. In this study, a total of 54 Chinese healthy participants are planned to be enrolled and randomly assigned to 2 dosing sequence groups (TRTR, and RTRT) in a 1:1 ratio, and administered once per cycle, with a washout period of at least 7 days, where T is the test formulation (the modified formulation) and R is the reference formulation (the original formulation).

The study will be divided into 3 periods: screening/baseline period, dosing period (four cycles), and follow-up period. The entire study from the screening period to the follow-up period is expected to last approximately 2 months.

Screening Period/Baseline Period The trial participants will sign a written informed consent form (ICF) on a voluntary basis prior to screening. Screening period/baseline period assessment will be completed within 14 days prior to the first dose. At screening/baseline, demographic data, medical history, medication history, allergy history, blood donation history, and participation in clinical trials should be collected, and physical examination, vital sign measurements, alcohol breath test, urine drug abuse screening, 12-lead ECG, infection markers [including hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, and Treponema pallidum antibody], laboratory tests (including hematology, blood chemistry, coagulation test, urinalysis), pregnancy test (female) and chest X-ray (frontal and lateral) examination will be performed. Only serious adverse events (SAEs) will be collected at screening/baseline.

Dosing Period (4 cycles) Eligible participants upon preliminary screening will be required to be admitted to the site 3 days before the first dose (i.e., 3 days prior to the initiation of the first cycle of medication). On the day of admission, vital sign measurements and inquiry about recent diet and medication, and pregnancy test (females only) will be performed to further verify the inclusion and exclusion criteria. According to the randomization scheme, eligible participants upon screening will be assigned a random number and randomly assigned to different dosing sequences (TRTR or RTRT). Based on the randomized dosing regimen, participants in different groups will take the test formulation or the reference formulation respectively after intake of breakfast (standard meal) on the first day of each cycle. The dosing regimen is detailed in the table below.

Crossover dosing regimen Group Number of participants Intake of standard meal breakfast Cycle 1 Cycle 2 Cycle 3 Cycle 4 TRTR 27 T R T R RTRT 27 R T R T

Method of administration:

Participants will fast for at least 10 hours before a standard meal on the first day of each cycle, start having a standard meal 30 minutes before dosing, and finish the meal within 25 minutes. After the meal, participants will have blank blood samples collected, and take the medication with about 240 mL of water on time 30 minutes after the meal. Except for the above-mentioned water for medication, participants are deprived of water is prohibited from 1 hour prior to the medication to 1 hour after the medication, and deprived of food within 4 hours after the medication. During hospitalization, the diet of the participants will be provided by the site.

The dosing period consists of four cycles, and the scheduled PK blood sampling time points for each participant in each cycle is as follows: within 0.5 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60, 72 hours post-dose, with a total of 18 collections (see Table 2 for details), and about 3 mL of venous blood collected each time.

After the participants are admitted to the clinical study ward, the vital sign measurements will be performed 1 day pre-dose in each cycle and 3±1 hours post-dose on the first day of each cycle. In addition, vital sign measurements, blood chemistry, and hematology will be performed on the Day 4 of the each of the first three cycles. On Cycle 4 Day 4, the participants will be discharged after vital sign measurements, physical examination, laboratory tests, and 12-lead ECG examination are completed.

Follow-up Period Participants will be followed up to Day 12±2 after the last dose (the day of the last dose is defined as Day 1 of follow-up period). The investigator will collect all AEs and concomitant medications/therapies from the participants during this period through telephone calls (or other means such as text messages). If there are AEs ongoing at follow-up, follow-up will continue until return to normal level, abnormal, not clinically significant, baseline level, stable or lost to follow-up, or refusal to visit, etc.,

02

Conditions studied

  • Healthy

Keywords

  • HMPL-523
03

In context

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Trial participants must meet all of the following criteria for enrollment:

  1. Participants can communicate well with the investigator, must voluntarily sign the ICF and agree to comply with the requirements of the study protocol;
  2. Male and female healthy participants aged 18-45 years (inclusive);
  3. Body weight ≥ 45 kg (females) or ≥ 50 kg (males), (BMI) 19-26 kg/m2 (inclusive);
  4. Study participants must commit to using highly effective for both themselves and their sexual partners during the study, and for 180 days after the end of the last study dose, and must not engage in sperm donation, egg donation, or have birth plan.

Exclusion criteria

Exclusion Criteria:

Study participants must be excluded from this study if one of the following conditions is met:

  1. Abnormal and results of vital signs, physical examination, 12-lead , chest X-ray (frontal and lateral), laboratory tests (including hematology, blood chemistry, urinalysis, etc.) or serum creatinine above the at screening;
  2. Positive for any of the , antibody, antibody, or Treponema pallidum antibody;
  3. History or current evidence of severe or chronic metabolic/endocrine, hepatic, renal, hematological, pulmonary, immunological, cardiovascular, gastrointestinal, genitourinary, neurological or psychiatric diseases;
  4. Prior history of hypertension;
  5. Prior history of severe gastrointestinal diseases such as dysphagia, active gastric ulcers, etc., resulting in inability to take oral medication or disorders in absorption of oral medication
  6. Prior history of gastrointestinal surgery, renal surgery, cholecystectomy, etc. that, in the judgment of the investigator, may affect drug absorption or excretion;
  7. Prior history of drug allergy, or acute allergic rhinitis or food allergy within 2 weeks before screening, or allergy to the active ingredients or of the study drug;
  8. Use of any prescription drugs and Chinese herbal medicines within 30 days prior to the first dose;
  9. Use of any over-the-counter drugs, vitamins, and health products within 14 days prior to the first dose;
  10. Consumption of more than 10 cigarettes per day within 3 months before screening, or those who cannot quit smoking during the study;
  11. Regular alcohol consumption within 6 months before screening, that is, those who drink more than 14 units of alcohol per week (1 unit = 360 mL of beer, or 45 mL of spirits with an alcohol content of 40%, or 150 mL of wine), or those who cannot abstain from alcohol during the study, or those who are positive for alcohol breath test;
  12. History of drug abuse or recreational use, or positive for urine drug abuse screen;
  13. Blood donation (including blood component donation) or blood loss ≥ 400 mL within 3 months prior to screening, blood products within 2 months prior to screening, blood donation (including component blood donation) or lost blood ≥ 200 mL within 1 month prior to screening, or a plan to donate blood or blood components during the study or within 1 month after the end of the study;
  14. Difficulty in blood collection, or a history of needle phobia or blood phobia, or intolerance to blood sampling via venipuncture, or poor evaluation of venous blood collection;
  15. Participants who participated in clinical studies of other drugs/medical devices and received drugs within 3 months prior to screening;
  16. Participants who have consumed foods, juices or drinks containing alcohol, grapefruit, Seville oranges and caffeine within 72 hours before the first dose, or cannot avoid them during the study;
  17. Those who have received within 8 weeks prior to screening or have plans to vaccinate during the clinical study;
  18. Those who have special requirements for diet and cannot accept unified dietary arrangements;
  19. Pregnant or lactating women, or those with blood pregnancy test results above the upper limit of normal during screening, or women with unprotected sex within 2 weeks prior to dosing;
  20. The study participant, based on the judgment of the investigator, has any other diseases or conditions that may affect the normal completion of the study or the evaluation of study data, or other conditions that make him/her unsuitable for participation in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Other
    TRTR

    Total 54 Chinese healthy participants are planned to be enrolled and randomly assigned to 2 dosing sequence groups (TRTR, and RTRT) in a 1:1 ratio and administered once per cycle, with a washout period of at least 7 days, where T is the test formulation (the modified formulation) and R is the reference formulation (the original formulation). the dose is 300mg for each cycle, and there were 4 cycles for each participant.

    Drug: HMPL-523 Acetate Tablets (Test Formulation) · Drug: HMPL-523 Acetate Tablets (Reference Formulation)

  • Other
    RTRT

    Total 54 Chinese healthy participants are planned to be enrolled and randomly assigned to 2 dosing sequence groups (TRTR, and RTRT) in a 1:1 ratio and administered once per cycle, with a washout period of at least 7 days, where T is the test formulation (the modified formulation) and R is the reference formulation (the original formulation). the dose is 300mg for each cycle, and there were 4 cycles for each participant.

    Drug: HMPL-523 Acetate Tablets (Test Formulation) · Drug: HMPL-523 Acetate Tablets (Reference Formulation)

Interventions

  • DrugHMPL-523 Acetate Tablets (Test Formulation)

    The trial participants were administered the drug on the first day of each cycle. dose 300mg

  • DrugHMPL-523 Acetate Tablets (Reference Formulation)

    The trial participants were administered the drug on the first day of each cycle. dose 300mg

06

What researchers measure

Primary outcomes

  1. PK parameters

    area under the plasma concentration-time curve from 0 to the time point t when the last concentration can be accurately measured (AUC0-t)

    Time frame: up to two months

  2. PK parameters

    area under the plasma concentration-time curve from 0 to infinity (AUC0-∞)

    Time frame: up to two months

  3. PK parameters

    maximum concentration (Cmax)

    Time frame: up to two months

  4. PK parameters

    time to maximum concentration (Tmax)

    Time frame: up to two months

  5. PK parameters

    terminal elimination half-life (t1/2)

    Time frame: up to two months

  6. The bioequivalence of two different drug product formulations of HMPL 523 acetate tablets

    It will be evaluated based on the area under the plasma concentration-time curve (AUC) and Cmax.

    Time frame: up to two months

Secondary outcomes

  1. To compare the relative bioavailability of two different drug product formulations of 300 mg (100 mg/tablet × 3) HMPL-523 acetate tablets

    Relative bioavailability (ratio of AUC of two different HMPL-523 acetate tablets)

    Time frame: up to two months

  2. Adverse events (AEs)

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: up to two months

  3. Laboratory tests

    Number of participants with abnormal laboratory tests results

    Time frame: up to two months

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University
    Jinan, Shandong 250014, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Nov 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Jan 9, 2026
StartActual
Oct 28, 2025
Primary completionActual
Nov 28, 2025
CompletionActual
Feb 2, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07331194
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Oct 28, 2025
Primary completion
Nov 28, 2025
Completion
Feb 2, 2026
Last update
Feb 12, 2026

Study contacts

Bin Yang
study director · Hutchmed

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion